SABCS 2026｜口头报告题目公布，General Session与Rapid Fire专场全梳理

12月9日 9:30–11:45（当地时间）｜Hall 1｜主持：William M Sikov、Laura M. Spring

GS1-1：External Validation of a Causal Multi-Modal AI Model for Prognosis and Chemotherapy Benefit in Node-Negative HR+/HER2- Breast Cancer Patients: Analysis of TAILORx

淋巴结阴性HR+/HER2-乳腺癌患者预后与化疗获益的因果多模态AI模型的外部验证：TAILORx分析

讲者：Nancy Chan, NYU Langone Health, New York, NY

GS1-2：Blinded validation of a causal multi-modal AI model in postmenopausal, node-positive, HR+ breast cancer: analysis of SWOG-8814

因果多模态AI模型在绝经后、淋巴结阳性、HR+乳腺癌中的盲法验证：SWOG-8814分析

讲者：Alastair M Thompson, Baylor College of Medicine, Houston, TX

GS1-3：Discussant for 1411 and 1420

讨论点评（针对摘要1411与1420）

讲者：Frederick M. Howard

GS1-4：Efficacy results of the SWOG-S1418 / NRG Oncology BR006 randomized Phase III trial evaluating adjuvant Pembrolizumab for triple negative breast cancer with residual disease after neoadjuvant chemotherapy

评估辅助帕博利珠单抗用于新辅助化疗后仍有残留病灶的三阴性乳腺癌的SWOG-S1418/NRG Oncology BR006随机Ⅲ期试验疗效结果

讲者：Lajos Pusztai, Yale School of Medicine, New Haven, CT

GS1-5：Neoadjuvant Famitinib in combine with Camrelizumab and chemotherapy in Triple Negative breast cancer (BCTOP-T-N01): a multicentre, randomized, phase 3 trial

法米替尼联合卡瑞利珠单抗及化疗新辅助治疗三阴性乳腺癌（BCTOP-T-N01）：一项多中心、随机、Ⅲ期试验

讲者：李俊杰，复旦大学附属肿瘤医院，中国

GS1-6：Results of phase II NeoTRACT trial: Neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC)

NeoTRACT Ⅱ期试验结果：基于肿瘤浸润淋巴细胞及治疗反应适应性调整的新辅助化学免疫治疗用于三阴性乳腺癌

讲者：Priyanka Sharma, University of Kansas Medical Center, Westwood, KS

GS1-7：Discussant for 916

讨论点评（针对摘要916）

讲者：Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands

GS1-8：First-line sacituzumab tirumotecan (sac-TMT) vs chemotherapy in unresectable recurrent or metastatic triple-negative breast cancer (TNBC) with PD-L1 CPS <10 or prior early-stage PD-(L)1 exposure: randomized phase 3 OptiTROP-Breast03 trial

芦康沙妥珠单抗（sac-TMT）对比化疗一线治疗PD-L1 CPS＜10或早期阶段曾接受PD-(L)1治疗的不可切除复发或转移性三阴性乳腺癌：随机Ⅲ期OptiTROP-Breast03试验

讲者：范蕾，复旦大学附属肿瘤医院，中国

12月10日 9:30–11:45（当地时间）｜Hall 1｜主持：Richard C Zellars、Alastair Thompson

GS2-1：Omission of Breast Surgery in HER2-Positive Primary Breast Cancer Achieving Clinical Complete Response After Anti-HER2-Based Therapy: Primary Results From the AMATERAS-BC Prospective Phase III Trial (JCOG1806)

HER2阳性原发性乳腺癌经抗HER2为基础的治疗达临床完全缓解后豁免乳房手术：AMATERAS-BC前瞻性Ⅲ期试验（JCOG1806）的主要结果

讲者：Tomomi Fujisawa, Gunma Prefectural Cancer Center, Gunma, Japan

GS2-2：Discussant for 979

讨论点评（针对摘要979）

讲者：Henry M Kuerer, UT MD Anderson Cancer Center, Houston, TX

GS2-3：PROSPECT: post-operative radiotherapy omission in selected patients with early breast cancer trial (ANZ 1002). Final results.

PROSPECT：早期乳腺癌特定人群豁免术后放疗研究（ANZ 1002）的最终结果

讲者：Bruce Mann, The Royal Melbourne Hospital, Parkville, Australia

GS2-4：NeoNod2 trial: initial oncologic outcomes following omission of axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases after neoadjuvant therapy

NeoNod2试验：新辅助治疗后前哨淋巴结微转移的乳腺癌患者省略腋窝淋巴结清扫的初步肿瘤学结局

讲者：Corrado Tinterri, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy

GS2-5：Results of the POSNOC Trial: Omission of Axillary Treatment in Patients Undergoing Breast-Conserving Surgery or Mastectomy with One or Two Sentinel Node Macrometastases

POSNOC试验结果：保乳手术或全乳切除、仅有1～2枚前哨淋巴结宏转移的患者省略腋窝治疗

讲者：Amit Goyal, Royal Derby Hospital, Derby, United Kingdom

12月11日 9:15–11:45（当地时间）｜Hall 1｜主持：Sarat Chandarlapaty、Shou-Ching Tang

GS3-3：Discussant

讨论点评

讲者：Aditya Bardia, University of California Los Angeles, Los Angeles, CA

GS3-4：Characterization of clinical outcomes in monarchE by histologic, molecular, and genomic subtypes: Updated baseline tumor analysis from patients with HR+, HER2−, node-positive, high-risk early breast cancer

monarchE研究中按组织学、分子及基因组亚型划分的临床结局特征：HR+、HER2−、淋巴结阳性高危早期乳腺癌患者基线肿瘤分析的更新结果

讲者：Nick Turner, Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

GS3-5：Longitudinal analysis of imaging biomarkers and ctDNA to predict neoadjuvant therapy response: a retrospective study from I-SPY 2

影像生物标志物与ctDNA的纵向分析预测新辅助治疗反应：I-SPY 2回顾性研究

讲者：Wen Li, University of California, San Francisco, San Francisco, CA

GS3-6：Translational discovery and validation of genomic alterations associated with AKT inhibitor (AKTi) resistance in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- MBC)

激素受体阳性、HER2阴性转移性乳腺癌中与AKT抑制剂耐药相关基因组改变的转化医学发现与验证

讲者：Maxwell R Lloyd, Massachusetts General Hospital, Boston, MA

GS3-7：Vaccination to target PARP inhibitor resistance caused by BRCA1/2 reversion mutations

针对BRCA1/2回复突变所致PARP抑制剂耐药的疫苗接种策略

讲者：Stephen J. Pettitt, Institute of Cancer Research, London, United Kingdom

GS3-8：Efficacy and safety of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy versus standard of care (SoC) therapy in stage I-II HER2+ early breast cancer (eBC): First results from WSG ADAPT-HER2-IV

新辅助德曲妥珠单抗（T-DXd）单药对比标准治疗用于Ⅰ～Ⅱ期HER2阳性早期乳腺癌的疗效与安全性：WSG ADAPT-HER2-IV研究首次结果

讲者：Nadia Harbeck, LMU University Hospital, Munich, Germany

GS3-10：The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab – Outcomes in Patients (pts) with HER2+ Metastatic Breast Cancer (MBC) (TBCRC 062)

STOP-HER2试验：停用曲妥珠单抗的Ⅱ期研究——HER2+转移性乳腺癌患者的结局（TBCRC 062）

讲者：Heather A Parsons, Fred Hutchinson Cancer Center, Seattle, WA

12月8日 16:30–17:30（当地时间）｜Stars at Night 1-2｜主持：Namita Chittoria、Hikmat Abdel-Razeq

RF1-1：Zanidatamab as a component of neoadjuvant therapy in HER2+ breast cancer: results from the I-SPY2.2 trial

zanidatamab作为HER2阳性乳腺癌新辅助治疗方案组成部分：I-SPY2.2试验结果

讲者：Anthony D Elias, University of Colorado, Aurora, CO

RF1-2：Event-free survival from the randomized phase 2 neoHIP trial evaluating neoadjuvant taxane, HER2-targeted therapy, +/- pembrolizumab in early-stage HER2-positive breast cancer

评估新辅助紫杉类联合抗HER2治疗±帕博利珠单抗用于早期HER2阳性乳腺癌的随机Ⅱ期neoHIP试验的无事件生存期

讲者：Heather L McArthur, UTSW, Dallas, TX

RF1-3：Circulating tumor DNA (ctDNA) dynamics and pathological complete response (pCR) in high-risk HER2+ early breast cancer (eBC) treated with neoadjuvant trastuzumab deruxtecan followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP): A DESTINY-Breast11 (DB-11) analysis

高危HER2阳性早期乳腺癌接受新辅助T-DXd序贯紫杉醇+曲妥珠单抗+帕妥珠单抗（T-DXd-THP）对比剂量密集多柔比星+环磷酰胺序贯THP（ddAC-THP）的ctDNA动态与病理完全缓解（pCR）：DESTINY-Breast11（DB-11）分析

讲者：Shanu Modi, Memorial Sloan Kettering Cancer Center, New York, NY

RF1-4：Optimising the duration of trastuzumab in early-stage HER2-positive breast cancer – an Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis

优化早期HER2阳性乳腺癌曲妥珠单抗的治疗时长——早期乳腺癌试验协作组（EBCTCG）荟萃分析

讲者：Rosie Bradley, University of Oxford, Oxford, United Kingdom

RF1-5：A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: First analysis of the ARIADNE trial

德曲妥珠单抗联合基于生物学特征的新辅助治疗选择用于HER2阳性乳腺癌的随机试验：ARIADNE试验首次分析

讲者：Theodoros Foukakis, Karolinska Institute, Stockholm, Sweden

RF1-6：PATINA (AFT-38): palbociclib benefit across key prespecified subgroups in HR+/HER2-positive advanced breast cancer – final protocol-specified PFS analysis

PATINA（AFT-38）：哌柏西利在HR+/HER2阳性晚期乳腺癌关键预设亚组中的获益——最终方案预设无进展生存期（PFS）分析

讲者：Otto Metzger, Dana-Farber Cancer Institute, Boston, MA

RF1-7：The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab – Outcomes in Patients with HER2+ Metastatic Breast Cancer (MBC) (TBCRC 062)

STOP-HER2试验：停用曲妥珠单抗的Ⅱ期研究——HER2阳性转移性乳腺癌患者的结局（TBCRC 062）

讲者：Heather A Parsons, Fred Hutchinson Cancer Center, Seattle, WA

12月8日 17:30–18:30（当地时间）｜Stars at Night 1-2｜主持：Yara Abdou、David Rimm

RF2-1：Updated Overall Survival (OS) Analysis from the Phase 3 ASCENT-07 Study of Sacituzumab Govitecan in Participants with HR+/HER2- Inoperable, Locally Advanced, or Metastatic Breast Cancer Post Endocrine Therapy

Ⅲ期ASCENT-07研究的总生存期（OS）更新分析：戈沙妥珠单抗治疗内分泌治疗后的HR+/HER2-不可手术、局部晚期或转移性乳腺癌

讲者：Hope S Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA

RF2-2：Prognostic and predictive value of key immunohistochemistry (IHC) protein biomarker expression levels in the NATALEE trial of adjuvant ribociclib (RIB) and nonsteroidal aromatase inhibitor (NSAI) in hormone receptor-positive/human epidermal growth factor receptor 2−negative early breast cancer (HR+/HER2− EBC)

NATALEE研究中关键免疫组化（IHC）蛋白生物标志物表达水平的预后与预测价值：辅助瑞波西利联合非甾体类芳香化酶抑制剂（NSAI）治疗HR+/HER2-早期乳腺癌

讲者：Michael Press, USC, Los Angeles, CA

RF2-3：H&E-derived gene-expression multimodal multitask modeling predicts chemotherapy benefit, distant recurrence risk, and 21-gene recurrence score in TAILORx

基于H&E染色切片的基因表达多模态多任务建模预测TAILORx研究中的化疗获益、远处复发风险及21基因复发评分

讲者：Joseph Sparano, Icahn School of Medicine at Mount Sinai, New York, NY

RF2-4：Genomic Response-Guided Chemotherapy Omission After Neoadjuvant Ribociclib and Endocrine Therapy in High-Risk HR+/HER2− Early Breast Cancer: Updated Results from the Phase II SOLTI-UNICANCER RIBOLARIS Trial

高危HR+/HER2-早期乳腺癌新辅助瑞波西利联合内分泌治疗后依据基因组反应指导豁免化疗：Ⅱ期SOLTI-UNICANCER RIBOLARIS试验更新结果

讲者：Milana Arantza Bergamino Sirvén, Hospital Clinic de Barcelona / SOLTI / IDIBAPS, Barcelona, Spain

RF2-5：Prospective Validation of Modified PEPI Following Neoadjuvant Anastrozole: Five-Year Recurrence-free Survival (RFS) from Alliance A011106 (ALTERNATE)

新辅助阿那曲唑治疗后改良PEPI评分的前瞻性验证：Alliance A011106（ALTERNATE）试验的5年无复发生存（RFS）结果

讲者：Cynthia X Ma, Washington University in St. Louis, Saint Louis, MO

RF2-6：CDK2 mediates RB-independent entry into S phase and is a therapeutic target in ER+/RB-deficient, CDK4/6 inhibitor-resistant breast cancer

CDK2介导不依赖RB的S期进入，是ER阳性/RB缺失、CDK4/6抑制剂耐药乳腺癌的治疗靶点

讲者：Chang-Ching A Lin, UT Southwestern Medical Center, Dallas, TX

RF2-7：Results from KEYNOTE-B49: a phase 3, randomized, double-blind study of pembrolizumab (vs placebo) plus chemotherapy in participants with HR+/HER2− locally recurrent inoperable or metastatic breast cancer

KEYNOTE-B49结果：帕博利珠单抗（对比安慰剂）联合化疗治疗HR+/HER2-局部复发不可手术或转移性乳腺癌的Ⅲ期随机双盲研究

讲者：Peter Schmid, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

12月9日 16:30–17:30（当地时间）｜Stars at Night 1-2｜主持：Ana Christina Garrido-Castro、Alessandra Gennari

RF3-1：Clinical validation of a multimodal model for frontline therapeutic selection in breast cancer

用于乳腺癌一线治疗选择的多模态模型的临床验证

讲者：Luca Boscolo-Bielo, Memorial Sloan Kettering Cancer Center, New York, NY

RF3-2：A single cell and spatial atlas of preinvasive breast cancer

浸润前乳腺癌的单细胞与空间图谱

讲者：Aatish Thennavan, UT MD Anderson Cancer Center, Houston, TX

RF3-3：A Multi-cohort Comparison of Genomic, Clinical, and AI Models for Recurrence Prediction in Early Breast Cancer

早期乳腺癌复发预测中基因组模型、临床模型与AI模型的多队列比较

讲者：Lajos Pusztai, Yale University, New Haven, CT

RF3-4：Validation of Quantitative Standardized High Sensitivity (HS)-HER2 as a prognostic factor for outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer

定量标准化高灵敏度（HS）-HER2作为转移性乳腺癌德曲妥珠单抗（T-DXd）治疗结局预后因素的验证

讲者：Paolo Tarantino, Dana-Farber Cancer Institute, Boston, MA

RF3-5：Pretreatment spatial transcriptomic features associated with response to neoadjuvant HER2-targeted therapy in HER2-positive breast cancer

HER2阳性乳腺癌中与新辅助抗HER2治疗反应相关的治疗前空间转录组特征

讲者：Emilia Morales, Karolinska Institutet, Stockholm, Sweden

RF3-6：Artera Multimodal AI Digital Pathology Identifies Distant Metastasis and Late Recurrence Risk Beyond the Recurrence Score: External Validation in TAILORx

Artera多模态AI数字病理在复发评分之外识别远处转移与晚期复发风险：TAILORx研究外部验证

讲者：Rima Patel, Icahn School of Medicine at Mount Sinai, New York, NY

12月9日 17:30–18:30（当地时间）｜Stars at Night 1-2｜主持：Christos Vaklavas、Shaheenah Dawood

RF4-1：Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC): Final Analysis Results in the T2N0 Subgroup From the Phase 3 KEYNOTE-522 Study

高危早期三阴性乳腺癌新辅助帕博利珠单抗或安慰剂联合化疗、序贯辅助帕博利珠单抗或安慰剂：Ⅲ期KEYNOTE-522研究T2N0亚组最终分析结果

讲者：Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom

RF4-2：Long-term outcomes after pathological complete response (pCR) to neoadjuvant chemo-immunotherapy (NA-CIO) without adjuvant PD-1/PD-L1 inhibition in early-stage triple negative breast cancer: an individual patient pooled analysis

早期三阴性乳腺癌新辅助化学免疫治疗达到病理完全缓解（pCR）后未行辅助PD-1/PD-L1抑制治疗的长期结局：个体患者数据合并分析

讲者：Stephen J Luen, Peter MacCallum Cancer Centre, Melbourne, Australia

RF4-3：Whole-genome sequencing-defined homologous recombination deficiency predicts carboplatin benefit in early triple-negative breast cancer: long-term survival outcome and biomarker analysis of the phase III PEARLY trial (KCSG BR 15-1)

全基因组测序定义的同源重组缺陷预测早期三阴性乳腺癌的卡铂获益：Ⅲ期PEARLY试验（KCSG BR 15-1）的长期生存结局与生物标志物分析

讲者：Joohyuk Sohn, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

RF4-4：Efficacy and safety of bulumtatug fuvedotin (BFv, 9MW2821), a Nectin-4 antibody-drug conjugate (ADC), in patients with advanced triple-negative breast cancer (aTNBC) previously treated with antibody-drug conjugates (ADCs): a phase Ib dose optimization study (9MW2821-CP103)

Nectin-4抗体偶联药物（ADC）bulumtatug fuvedotin（BFv，9MW2821）用于既往接受过ADC治疗的晚期三阴性乳腺癌患者的疗效与安全性：Ⅰb期剂量优化研究（9MW2821-CP103）

讲者：Nour Abuhadra, Memorial Sloan Kettering Cancer Center, New York, NY

RF4-5：Phase II Study of Izalontamab Brengitecan (iza-bren) Combined with Toripalimab in Patients with Unresectable Locally Advanced, Recurrent or Metastatic Triple-Negative Breast Cancer (TNBC)

伦康依隆妥单抗（iza-bren）联合特瑞普利单抗治疗不可切除局部晚期、复发或转移性三阴性乳腺癌的Ⅱ期研究

讲者：张剑, 复旦大学附属肿瘤医院，中国

RF4-6：Safety and preliminary efficacy of SYS6010 monotherapy in patients with HER2-negative, EGFR-expressing breast cancer

SYS6010单药治疗HER2阴性、EGFR表达乳腺癌患者的疗效与安全性初步结果

讲者：张剑, 复旦大学附属肿瘤医院，中国

12月10日 16:30–17:30（当地时间）｜Stars at Night 1-2｜主持：Allison Kurian、Kimberley T Lee

RF5-2：De-escalated Denosumab (Every 12 versus Every 4 Weeks) Maintains Efficacy for Prevention of Symptomatic Skeletal Events in Patients with Bone Metastases: Breast Cancer Stratum from the Randomized Phase-III Non-Inferiority REDUSE Trial (SAKK 96/12)

地舒单抗降阶给药（每12周对比每4周）在预防骨转移患者症状性骨事件中的疗效得以维持：随机Ⅲ期非劣效REDUSE试验（SAKK 96/12）中的乳腺癌队列结果

讲者：Andreas Müller, Kantonsspital Winterthur, Winterthur, Switzerland

RF5-3：Pink! Leben: a randomized controlled trial of an acceptance and commitment therapy-based digital intervention for psychological distress in breast cancer patients across treatment phases

Pink! Leben：基于接纳承诺疗法的数字化干预改善不同治疗阶段乳腺癌患者心理痛苦的随机对照试验

讲者：Christian Schem, Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg, Germany

RF5-4：Quality of life for patients aged 40 or older with oestrogen receptor-positive HER2-negative early breast cancer and 0-9 involved axillary lymph nodes within the OPTIMA trial

OPTIMA试验中40岁及以上、雌激素受体阳性/HER2阴性、腋窝淋巴结受累0～9枚的早期乳腺癌患者的生活质量

讲者：Janet Audrey Dunn, University of Warwick, Coventry, United Kingdom

RF5-5：Temperature-controlled hand-foot cooling prevents chemotherapy-induced polyneuropathy (CIPN): updated real-world data collection in 600 patients

温控手足冷却预防化疗所致周围神经病变（CIPN）：600例患者的最新真实世界数据

讲者：Athina Kostara, MVZ Medical Center Duesseldorf, Duesseldorf, Germany

RF5-6：The role of estrogen plus progestogen on breast cancer incidence: a systematic review and meta-analysis of randomized clinical trials

雌激素联合孕激素对乳腺癌发病率的影响：随机临床试验的系统评价与荟萃分析

讲者：Margaret S Pichardo, University of Pennsylvania, Philadelphia, PA

RF5-7：Social drivers, age-at-onset, and later stage at diagnosis in association with aggressive RNA-based breast cancer subtypes among Black women

社会决定因素、发病年龄及诊断时分期较晚与黑人女性侵袭性RNA型乳腺癌亚型的关联

讲者：Sarah C Van Alsten, University of North Carolina at Chapel Hill, Chapel Hill, NC

12月10日 17:30–18:30（当地时间）｜Stars at Night 1-2｜主持：Rohini K. Bhatia、Roshni Rao

RF6-1：Interim event-free survival with peri-operative immune checkpoint inhibition and cryoablation in residual triple-negative breast cancer

残留三阴性乳腺癌围手术期免疫检查点抑制联合冷冻消融的中期无事件生存

讲者：Heather L McArthur, UTSW, Dallas, TX

RF6-2：Breast-MRI trial: the paradox of preoperative breast MRI — more surgery, no detectable survival benefit in a randomized trial

Breast-MRI试验：术前乳腺MRI的悖论——随机试验中更多的手术干预，却未见可检测的生存获益

讲者：Bruna S Mota, ICESP, Sao Paulo, Brazil

RF6-3：Technical outcomes of node marking and targeted axillary dissection after neoadjuvant chemotherapy in node-positive breast cancer: results from 1295 participants in the ATNEC trial

淋巴结阳性乳腺癌新辅助化疗后淋巴结标记与靶向腋窝清扫的技术结局：ATNEC试验1295例参与者结果

讲者：Amit Goyal, Royal Derby Hospital, Derby, United Kingdom

RF6-4：Prediction of pathological tumor size in 2,138 breast cancer patients treated with breast-conserving surgery: comparative analysis of preoperative imaging modalities in the prospective multicenter MELODY (EUBREAST-4 / iBRA-NET / AGO-B-062) study

2138例接受保乳手术的乳腺癌患者病理肿瘤大小预测：前瞻性多中心MELODY（EUBREAST-4/iBRA-NET/AGO-B-062）研究中术前影像学检查的比较分析

讲者：Nikolas Tauber, University of Luebeck, Luebeck, Germany

RF6-5：Axillary Radiotherapy as an Alternative to Axillary Lymph Node Dissection in Sentinel Node-Positive Breast Cancer Patients After Neoadjuvant Therapy: Three-Year Outcomes from the ADARNAT Pilot Randomized Trial

腋窝放疗替代腋窝淋巴结清扫用于新辅助治疗后前哨淋巴结阳性的乳腺癌患者：ADARNAT探索性随机试验的3年结局

讲者：Amparo Garcia-Tejedor, Bellvitge Hospital, L'Hospitalet de Llobregat, Spain

RF6-6：One-week or three-week Adjuvant Radiation in Breast Cancer (OTHAR) – A Phase III Non-Inferiority Randomized controlled Trial – Early outcomes and Acute Toxicity Results

一周或三周辅助放疗治疗乳腺癌（OTHAR）——Ⅲ期非劣效随机对照试验的早期结局与急性毒性结果

讲者：Supriya Mallick, National Cancer Institute-All India Institute of Medical Sciences, New Delhi, India

RF6-7：Oncological safety of breast-conserving surgery following neo-adjuvant chemotherapy in locally advanced breast cancer: Results from a randomized controlled trial

局部晚期乳腺癌新辅助化疗后保乳手术的肿瘤学安全性：一项随机对照试验结果

讲者：Ankita Manan Sheth, Tata Memorial Hospital, Mumbai, India

12月11日 13:00–14:00（当地时间）｜Stars at Night 1-2｜主持：Reshma L Mahtani

RF7-1：Treatment discontinuations and patient-reported outcomes in lidERA Breast Cancer: A Phase III trial of giredestrant in patients with estrogen receptor-positive, HER2-negative early breast cancer

lidERA乳腺癌研究中的治疗中断与患者报告结局：giredestrant用于雌激素受体阳性、HER2阴性早期乳腺癌的Ⅲ期试验

讲者：Sara A Hurvitz, Fred Hutchinson Cancer Center, Seattle, WA

RF7-2：Efficacy and Safety of a 6-Month Pre-mixed Depot formulation, Leuprorelin Mesylate Injection (6M) with Tamoxifen in Premenopausal HR+ Breast Cancer: A Phase III, Randomized, Open-Label, Non-Inferiority Study in China

6个月预混长效制剂醋酸亮丙瑞林微球注射液（6M）联合他莫昔芬治疗绝经前HR+乳腺癌的疗效与安全性：中国Ⅲ期、随机、开放标签、非劣效性研究

讲者：张剑，复旦大学附属肿瘤医院，中国

RF7-3：I-SPY 2 Endocrine Optimization Pilot (EOP): elagolix vs GnRH agonist as ovarian function suppression (OFS) in premenopausal patients receiving neoadjuvant (Z)-endoxifen for estrogen receptor positive (ER+)/HER2 negative stage 2/3 breast cancer

I-SPY 2内分泌优化先导研究（EOP）：elagolix对比GnRH激动剂作为卵巢功能抑制（OFS），用于接受新辅助（Z）-endoxifen治疗的ER+/HER2- 2/3期乳腺癌绝经前患者

讲者：Annabelle Duflock, University of California, San Francisco, San Francisco, CA

RF7-4：A randomised non-comparative phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES); EORTC-1745-ETF-BCG

辅助哌柏西利替代化疗用于高危ER+/HER2-早期乳腺癌老年患者的随机非比较Ⅱ期研究（APPALACHES；EORTC-1745-ETF-BCG）

讲者：Hans Wildiers, University Hospitals Leuven, Leuven, Belgium

RF7-5：Afuresertib and fulvestrant for PIK3CA/AKT1/PTEN-altered, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III part of LAE205INT3101 trial

阿氟色替联合氟维司群治疗PIK3CA/AKT1/PTEN改变、激素受体阳性/HER2阴性晚期乳腺癌：LAE205INT3101试验Ⅲ期部分结果

讲者：张频，中国医学科学院肿瘤医院，中国

RF7-7：Updated Efficacy Results From LEONARDA-2: A Phase III, Randomized, Placebo-Controlled Trial of Lerociclib Plus Letrozole as First-Line Therapy for HR+/HER2- Advanced Breast Cancer

LEONARDA-2更新疗效结果：来罗西利联合来曲唑一线治疗HR+/HER2-晚期乳腺癌的Ⅲ期随机安慰剂对照试验

讲者：胡夕春，复旦大学附属肿瘤医院，中国

注：本文题目与报告人信息整理自SABCS会议官网，内容截至发稿之日（2026年10月31日）。各专场摘要编号中存在个别跳号（如上表所列编号原样保留），会议议程、报告时间与编号或有更新，最终信息请以大会官方发布为准；研究数据将于会议期间公布。